Patients showing a normal value of SDI (\< or + 8%) will randomly be assigned to CRT in "ON" or "OFF"mode at one month after implantation. In any case of emergency, an automated rescue mode is included in the device for the patients in "OFF" mode.
Patients with a pathological SDI (\> 8%) will as usually be treated by CRT and will serve as control group. The study duration for each patient included in the trial is 6 months. Patients showing a decreased NYHA score by at least one class and an absence of major cardiovascular event during the period will be considered as "good responders". The otherswill be considered as "no responders". Based on this composite clinical score, the percentage of good responders in each group at 6 months is the primary endpoint of the study. Main secondary endpoints : * Evaluation of the left ventricular function * Exercice capacity * Serious adverse events'frequency * Quality of life (SF36) * Diagnostic and prognostic value of the "Brain Natriuretic Peptide"(NT pro BNP)evolution.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
SINGLE
Clermont-Ferrand University Hospital
Clermont-Ferrand, Auvergne, France
Three parallel arms, randomized, controlled, single blinded, monocentre, clinical trial.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.